These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9808686)

  • 1. Anandamide, an endogenous cannabinoid, has a very low physical dependence potential.
    Aceto MD; Scates SM; Razdan RK; Martin BR
    J Pharmacol Exp Ther; 1998 Nov; 287(2):598-605. PubMed ID: 9808686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs.
    Lichtman AH; Wiley JL; LaVecchia KL; Neviaser ST; Arthur DB; Wilson DM; Martin BR
    Eur J Pharmacol; 1998 Sep; 357(2-3):139-48. PubMed ID: 9797029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride].
    Shivachar AC; Martin BR; Ellis EF
    Biochem Pharmacol; 1996 Mar; 51(5):669-76. PubMed ID: 8615904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
    Adams IB; Compton DR; Martin BR
    J Pharmacol Exp Ther; 1998 Mar; 284(3):1209-17. PubMed ID: 9495885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide.
    Järbe TU; Lamb RJ; Lin S; Makriyannis A
    Psychopharmacology (Berl); 2001 Aug; 156(4):369-80. PubMed ID: 11498713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid.
    Calignano A; La Rana G; Makriyannis A; Lin SY; Beltramo M; Piomelli D
    Eur J Pharmacol; 1997 Dec; 340(2-3):R7-8. PubMed ID: 9537804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
    Wagner JA; Járai Z; Bátkai S; Kunos G
    Eur J Pharmacol; 2001 Jul; 423(2-3):203-10. PubMed ID: 11448486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of anandamide hypotension by the transport inhibitor, AM404.
    Calignano A; La Rana G; Beltramo M; Makriyannis A; Piomelli D
    Eur J Pharmacol; 1997 Oct; 337(1):R1-2. PubMed ID: 9389389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity.
    Compton DR; Martin BR
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1138-43. PubMed ID: 9399986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356).
    Järbe TU; Lamb RJ; Liu Q; Makriyannis A
    Psychopharmacology (Berl); 2006 Oct; 188(3):315-23. PubMed ID: 16953384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
    Järbe TU; Lamb RJ; Liu Q; Makriyannis A
    Eur J Pharmacol; 2003 Apr; 466(1-2):121-7. PubMed ID: 12679148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of Δ9-Tetrahydrocannabinol and Anandamide on a Battery of Cognition-Related Behavior in Nonhuman Primates.
    Kangas BD; Leonard MZ; Shukla VG; Alapafuja SO; Nikas SP; Makriyannis A; Bergman J
    J Pharmacol Exp Ther; 2016 Apr; 357(1):125-33. PubMed ID: 26826191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
    Welch SP; Huffman JW; Lowe J
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery.
    White R; Hiley CR
    Br J Pharmacol; 1997 Dec; 122(8):1573-84. PubMed ID: 9422801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.
    Aceto MD; Scates SM; Lowe JA; Martin BR
    Eur J Pharmacol; 1995 Aug; 282(1-3):R1-2. PubMed ID: 7498260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes.
    Oz M; Yang KH; Dinc M; Shippenberg TS
    J Pharmacol Exp Ther; 2007 Nov; 323(2):547-54. PubMed ID: 17682128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic and portal hemodynamic effects of anandamide.
    Garcia N; Járai Z; Mirshahi F; Kunos G; Sanyal AJ
    Am J Physiol Gastrointest Liver Physiol; 2001 Jan; 280(1):G14-20. PubMed ID: 11123193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors.
    Williams CM; Kirkham TC
    Psychopharmacology (Berl); 1999 Apr; 143(3):315-7. PubMed ID: 10353436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precipitated and spontaneous withdrawal in rats tolerant to anandamide.
    Costa B; Giagnoni G; Colleoni M
    Psychopharmacology (Berl); 2000 Apr; 149(2):121-8. PubMed ID: 10805606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats.
    Smith FL; Fujimori K; Lowe J; Welch SP
    Pharmacol Biochem Behav; 1998 May; 60(1):183-91. PubMed ID: 9610941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.